

Sarit Assouline

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6050743/publications.pdf>

Version: 2024-02-01

147
papers

7,159
citations

101543

36
h-index

60623

81
g-index

147
all docs

147
docs citations

147
times ranked

8884
citing authors

#	ARTICLE	IF	CITATIONS
1	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	5.2	77
2	B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. <i>Vaccine</i> , 2022, 40, 1203-1207.	3.8	11
3	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	1.6	160
4	Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments. <i>Critical Reviews in Oncology/Hematology</i> , 2022, , 103711.	4.4	1
5	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. <i>Blood</i> , 2022, 140, 839-850.	1.4	55
6	Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
7	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 1055-1065.	10.7	119
8	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study. <i>Leukemia Research</i> , 2021, 100, 106489.	0.8	29
9	A review of FDA-approved acute myeloid leukemia therapies beyond $\hat{\sim}7 + 3\hat{\sim}$. <i>Expert Review of Hematology</i> , 2021, 14, 185-197.	2.2	30
10	Risk of infection in $\langle \text{MPN} \rangle$ patients in the era of $\langle \text{COVID} \rangle$: A prospective multicenter study of $\langle 257 \rangle$ patients from the $\langle \text{CML} \rangle$ $\langle \text{MPN} \rangle$ $\langle \text{UEBEC} \rangle$ $\langle \text{RESEARCH} \rangle$ $\langle \text{GROUP} \rangle$. <i>American Journal of Hematology</i> , 2021, 96, E200-E203.	4.1	2
11	A $\langle \text{Phase I} \rangle$ dose-escalation study of $\langle \text{DCLL9718S} \rangle$, an antibody-drug conjugate targeting $\langle \text{CLC} \rangle$ -type lectin-like molecule $\langle 1 \rangle$ ($\langle \text{CLL} \rangle$ $\langle 1 \rangle$) in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E175-E179.	4.1	3
12	Treating lymphoma is now a bit EZ-er. <i>Blood Advances</i> , 2021, 5, 2256-2263.	5.2	22
13	Clinical outcomes after 4.5% years of eliglustat therapy for $\langle \text{Gaucher} \rangle$ disease type 1: Phase 3 $\langle \text{ENGAGE} \rangle$ trial final results. <i>American Journal of Hematology</i> , 2021, 96, 1156-1165.	4.1	22
14	IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S406-S407.	0.4	0
15	CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma. <i>Translational Oncology</i> , 2021, 14, 101188.	3.7	9
16	Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG. <i>Blood</i> , 2021, 138, 220-220.	1.4	0
17	A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy. <i>Blood</i> , 2021, 138, 3610-3610.	1.4	3
18	TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data. <i>Blood</i> , 2021, 138, 2488-2488.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. <i>Blood</i> , 2021, 138, 1476-1476.	1.4	1
20	Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 127-127.	1.4	20
21	Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 3573-3573.	1.4	7
22	Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd. <i>Blood</i> , 2021, 138, 4602-4602.	1.4	2
23	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 155-165.	1.6	488
24	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4042-4054.	1.6	141
25	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	10.7	306
26	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.	3.7	28
27	An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 933-942.	2.2	1
28	Rituximab-induced autoimmune hepatitis: A case study and literature review. <i>Canadian Liver Journal</i> , 2020, 3, 381-386.	0.9	4
29	Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020, 191, 44-51.	2.5	19
30	The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. <i>Blood Advances</i> , 2020, 4, 2011-2017.	5.2	12
31	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. <i>Blood</i> , 2020, 136, 2237-2240.	1.4	13
32	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1653-1659.	1.3	6
33	Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2886-2898.	5.2	59
34	Chronic myelogenous leukemia presenting as central retinal vein occlusion. <i>Leukemia and Lymphoma</i> , 2020, 61, 2515-2518.	1.3	1
35	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	4.1	12
36	Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. <i>Investigational New Drugs</i> , 2020, 38, 1430-1441.	2.6	10

#	ARTICLE	IF	CITATIONS
37	PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma. Current Treatment Options in Oncology, 2020, 21, 51.	3.0	27
38	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist, 2020, 25, e993-e997.	3.7	7
39	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematology, 2019, 6, e254-e265.	4.6	184
40	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology, 2019, 37, 481-489.	1.6	265
41	An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. British Journal of Haematology, 2019, 184, 215-222.	2.5	35
42	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. British Journal of Haematology, 2019, 185, 595-598.	2.5	19
43	Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study. Blood, 2019, 134, 4081-4081.	1.4	10
44	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase Ib Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Blood, 2019, 134, 229-229.	1.4	30
45	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Blood, 2019, 134, 6-6.	1.4	152
46	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3) Tj ETQq0 0 0 rgBT /Overlock 1 4728-4728.	1.4	3
47	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 355-355.	1.4	16
48	Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial. Blood, 2019, 134, 3905-3905.	1.4	7
49	Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral. Blood, 2019, 134, 768-768.	1.4	2
50	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. Blood, 2019, 134, 29-29.	1.4	2
51	Prediction of High-Risk Group of Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using a CT-Based Radiomics Model with Machine Learning. Blood, 2019, 134, 4136-4136.	1.4	1
52	Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP. Blood, 2019, 134, 921-921.	1.4	2
53	A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL). Blood, 2019, 134, 1593-1593.	1.4	4
54	CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas. Blood, 2019, 134, 1608-1608.	1.4	5

#	ARTICLE	IF	CITATIONS
55	Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1585-1585.	1.4	26
56	Changes in Tumor Immune Micro-Environment in Diffuse Large B-Cell Lymphoma (DLBCL): A Comparative Study of Relapsed Versus Diagnostic DLBCL. <i>Blood</i> , 2019, 134, 3968-3968.	1.4	2
57	Improving End of Life Care for Hematology-Oncology Patients within the Rossy Cancer Network. <i>Blood</i> , 2019, 134, 4775-4775.	1.4	0
58	Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg. <i>Blood</i> , 2019, 134, 1766-1766.	1.4	0
59	Improving on R-ICE in relapsed DLBCL. <i>Blood</i> , 2018, 131, 1767-1768.	1.4	1
60	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	1.3	11
61	Venetoclax + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1107-1120.	27.0	684
62	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	1.6	257
63	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E49-E52.	4.1	14
64	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 184-184.	1.4	8
65	Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months. <i>Blood</i> , 2018, 132, 461-461.	1.4	8
66	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	1.4	5
67	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. <i>Blood</i> , 2018, 132, 453-453.	1.4	1
68	Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idas) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. <i>Blood</i> , 2018, 132, 767-767.	1.4	21
69	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 1626-1626.	1.4	7
70	Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. <i>Blood</i> , 2018, 132, 399-399.	1.4	48
71	Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. <i>Blood</i> , 2018, 132, 1683-1683.	1.4	18
72	Hepatitis B Virus (HBV) Screening and Associated Outcomes in Malignant Hematology Patients Receiving Rituximab Therapy within the Rossy Cancer Network. <i>Blood</i> , 2018, 132, 2256-2256.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 93-93.	1.4	0
74	Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 218-221.	1.3	1
75	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S380-S381.	0.4	3
76	Subcutaneous rituximab a meaningful advance in care. <i>Lancet Haematology</i> , 2017, 4, e248-e249.	4.6	3
77	Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with acute myeloid leukemia type 1: The phase 3 ENGAGE trial. <i>American Journal of Hematology</i> , 2017, 92, 1170-1176.	4.1	77
78	The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity. <i>ELife</i> , 2017, 6, .	6.0	15
79	Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. <i>Blood</i> , 2017, 130, LBA-2-LBA-2.	1.4	14
80	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2016, 17, 612-621.	10.7	214
81	Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. <i>Lancet Haematology</i> , 2016, 3, e128-e138.	4.6	37
82	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. <i>Clinical Chemistry</i> , 2016, 62, 1238-1247.	3.2	45
83	Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia. <i>Journal of Oncology Practice</i> , 2016, 12, 592-594.	2.5	2
84	Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. <i>Haematologica</i> , 2016, 101, e185-e188.	3.5	68
85	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. <i>Clinical Cancer Research</i> , 2016, 22, 2290-2300.	7.0	186
86	Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. <i>Clinical Cancer Research</i> , 2016, 22, 868-876.	7.0	262
87	Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 2963-2963.	1.4	5
88	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016, 128, 4194-4194.	1.4	1
89	A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. <i>Haematologica</i> , 2015, 100, e7-e9.	3.5	64
90	Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. <i>American Journal of Hematology</i> , 2015, 90, 910-914.	4.1	181

#	ARTICLE	IF	CITATIONS
91	Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 627-634.e5.	0.4	6
92	Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1001-1009.	2.4	33
93	Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 704-715.	10.7	272
94	Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 695.	7.4	120
95	Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?. <i>Leukemia and Lymphoma</i> , 2015, 56, 6-7.	1.3	1
96	Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials. <i>Leukemia and Lymphoma</i> , 2015, 56, 2747-2749.	1.3	1
97	A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 59-74.	0.4	17
98	A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 2719-2719.	1.4	0
99	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. <i>American Journal of Hematology</i> , 2014, 89, 732-742.	4.1	102
100	Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study. <i>Leukemia and Lymphoma</i> , 2014, 55, 533-537.	1.3	16
101	Phase I/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lincatuzumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 258-265.	2.5	65
102	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. <i>Nature</i> , 2014, 511, 90-93.	27.8	168
103	Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). <i>Blood</i> , 2014, 124, 116-116.	1.4	55
104	Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma. <i>Blood</i> , 2014, 124, 1701-1701.	1.4	13
105	FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance. <i>Blood</i> , 2014, 124, 3018-3018.	1.4	1
106	Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 4457-4457.	1.4	26
107	Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). <i>Blood</i> , 2014, 124, 519-519.	1.4	30
108	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. <i>Blood</i> , 2014, 124, 813-813.	1.4	4

#	ARTICLE	IF	CITATIONS
109	Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341). <i>Blood</i> , 2014, 124, 1995-1995.	1.4	0
110	Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 4472-4472.	1.4	1
111	Engage - a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Eliglustat in Adults with Gaucher Disease Type 1: Results after 18 Months. <i>Blood</i> , 2014, 124, 2732-2732.	1.4	0
112	High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 676-683.	1.6	171
113	Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. <i>Frontiers in Pharmacology</i> , 2013, 4, 9.	3.5	4
114	Systemic cancer therapy: achievements and challenges that lie ahead. <i>Frontiers in Pharmacology</i> , 2013, 4, 57.	3.5	165
115	Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. <i>Blood</i> , 2013, 122, 1810-1810.	1.4	14
116	Engage: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Study To Investigate The Efficacy and Safety Of Eliglustat In Adults With Gaucher Disease Type 1: 9 Month Results. <i>Blood</i> , 2013, 122, 2275-2275.	1.4	1
117	Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine. <i>Blood</i> , 2013, 122, 498-498.	1.4	17
118	Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2013, 122, 4040-4040.	1.4	0
119	Accrual Of Patients With Relapsed and Refractory DLBCL Onto Clinical Trials. <i>Blood</i> , 2013, 122, 3041-3041.	1.4	0
120	A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1. <i>Blood</i> , 2013, 122, 821-821.	1.4	0
121	Impact Of Dedicated CML Clinic On The Outcome Of Patients With Newly Diagnosed CML: Experience Of a Single Canadian Center. <i>Blood</i> , 2013, 122, 5186-5186.	1.4	1
122	The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). <i>Cancers</i> , 2012, 4, 1161-1179.	3.7	8
123	Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab. <i>Blood</i> , 2012, 120, 1637-1637.	1.4	5
124	Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma. <i>Blood</i> , 2012, 120, 3646-3646.	1.4	3
125	MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study. <i>Blood</i> , 2012, 120, 3677-3677.	1.4	5
126	Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update. <i>Blood</i> , 2012, 120, 3785-3785.	1.4	4

#	ARTICLE	IF	CITATIONS
127	Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study. <i>Blood</i> , 2012, 120, 3822-3822.	1.4	14
128	Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia. <i>Blood</i> , 2012, 120, 675-675.	1.4	12
129	Monitoring Response and Resistance to Treatment in Chronic Myeloid Leukemia. <i>Current Oncology</i> , 2011, 18, 71-83.	2.2	29
130	A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 643-651.	2.3	15
131	Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 138-149.	4.4	103
132	Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2011, 52, 1010-1016.	1.3	6
133	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561.	6.3	362
134	A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). <i>Leukemia and Lymphoma</i> , 2011, 52, 394-399.	1.3	58
135	MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011, 118, 2672-2672.	1.4	1
136	Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years. <i>Blood</i> , 2011, 118, 3766-3766.	1.4	0
137	A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E. <i>Blood</i> , 2011, 118, 3606-3606.	1.4	0
138	A Canadian Expanded Access Trial of Oral Nilotinib in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase. <i>Blood</i> , 2011, 118, 4437-4437.	1.4	0
139	Oxalic acid excretion after intravenous ascorbic acid administration. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 263-269.	3.4	56
140	Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. <i>Blood</i> , 2009, 114, 257-260.	1.4	275
141	Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. <i>Haematologica</i> , 2008, 93, 317-318.	3.5	32
142	Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. <i>Leukemia and Lymphoma</i> , 2007, 48, 513-520.	1.3	17
143	Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient. <i>American Journal of Hematology</i> , 2006, 81, 646-646.	4.1	7
144	Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2006, 354, 2623-2624.	27.0	66

#	ARTICLE	IF	CITATIONS
145	High-dose vitamin C therapy: Renewed hope or false promise?. Cmaj, 2006, 174, 956-957.	2.0	18
146	Higher Prevalence of Prior Prostate Cancer in Patients Diagnosed with Chronic Myelogenous Leukemia.. Blood, 2006, 108, 4795-4795.	1.4	0
147	Children Who Can't Smell the Coffee: Isolated Congenital Anosmia. Journal of Child Neurology, 1998, 13, 168-172.	1.4	21